- Details
- Chiara Ciccarese discusses the TACITO-II trial results, evaluating fecal microbiota transplantation (FMT) in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. The phase II randomized study shows promising results, with FMT increasing the one-year progression-free survival rate from 35% to 66.7%. Dr. Ciccarese highlights the trial's novelty in demonstrating the tra...
|
- Details
- Matthew Galsky discusses preliminary results from the RC48G001 Study Cohort C, evaluating disitamab vedotin plus pembrolizumab in HER2-expressing metastatic urothelial cancer. The study shows a 75% response rate in treatment-naive patients, with activity observed in both HER2-positive and HER2-low tumors. The safety profile differs from enfortumab vedotin plus pembrolizumab, potentially offering a...
|
- Details
- Michael Hofman discusses the development of new criteria for evaluating prostate cancer progression using PSMA PET-CT scans. This work aims to standardize response evaluation and potentially replace the current PCWG3 guidelines that rely on CT and bone scans. Using data from the PRINCE trial, Dr. Hofman's team demonstrates high inter-reader agreement for the new criteria, with almost perfect agree...
|
- Details
- Axel Heidenreich discusses the final results of the COTRIMS trial, evaluating retroperitoneal lymph node dissection (RPLND) for clinical stage IIA and IIB seminomas. The study demonstrates high oncological efficacy with a 100% overall survival and 88% treatment-free survival after a median follow-up of three years. Dr. Heidenreich emphasizes the benefits of nerve-sparing RPLND, including preserved...
|
- Details
- Andrea Apolo discusses extended follow-up data from the AMBASSADOR trial. This phase 3 study evaluates adjuvant pembrolizumab versus observation in high-risk muscle-invasive urothelial carcinoma. With 45-month follow-up, pembrolizumab demonstrates significant improvement in disease-free survival (29.6 vs 14.2 months). The benefit is consistent across PD-L1 status and lymph node involvement subgrou...
|
- Details
- Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
|
- Details
- Eric Jonasch discusses data on NKT2152, a novel HIF-2 alpha inhibitor for clear cell renal cell carcinoma. The phase 1/2 study shows promising results in heavily pre-treated patients, with objective response rates around 25% and median progression-free survival of 7.4 months. Dr. Jonasch highlights the drug's efficacy across risk groups and its favorable safety profile, with anemia as the most com...
|
- Details
- Toni Choueiri discusses the TiNivo-2 trial results, comparing tivozanib-nivolumab combination to tivozanib monotherapy in advanced clear cell renal cell carcinoma. The study, involving 343 patients, shows no benefit in rechallenging with nivolumab after prior immunotherapy. Tivozanib monotherapy demonstrates efficacy, particularly in patients progressing directly from immunotherapy, with a progres...
|
- Details
- Dag Stormoen discusses research comparing genetic profiles of early and late-stage urothelial tract cancer. The study finds similar mutational profiles between muscle-invasive bladder cancer and heavily treated metastatic disease. Notably, a small cohort of advanced-stage patients showed unexpectedly long survival, with some living beyond five years. The research highlights the potential of geneti...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC). They highlight the new stratification of treatment recommendations based on disease volume and timing of metastases. The discussion covers recent clinical trials supporting triplet therapy for high-volume synchronous disease, inclu...
|
